CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
Chinese Antibody Society invites you to join our 2020 mAbTalk virtual symposium, “Revisiting the Perspectives on Bispecific Antibodies under the COVID-19 Pandemic", on Dec 5th, 2020.
Bispecific and multispecific antibody-based therapies are at the cutting-edge of therapeutic biologics development, and provide new opportunities to address unmet medical needs. In our one-day symposium, eight speakers from both industry and academia will share insights on all aspects of bispecific antibody-based therapeutic development, including novel targets and molecular formats, development of the lead candidate from discovery to clinics, CMC challenges and strategies, regulatory considerations, patent protection strategies, and COVID-19 related therapeutics. Online LIVE Q & A sessions will be included after every presentation.
We sincerely hope you can join us online on December 5th (US EST) to enjoy the state-of-the-art science and direct communication with experts in the field.
Hover above speaker cards to read bio
Kedan Lin, PhD
VP, Innovent Biologics
Mitchell Ho, PhD
Sr. Investigator, LMB, NCI
Audrey Jia, MD, PhD
Principal Consultant, DataRevive
Ting Xu, PhD
Founder/CEO, Alphamab Oncology
Yue Liu, PhD
Founder/CEO, Ab Studio and Ab Therapeutics
Paul Parren, PhD
Executive VP, Lava Therapeutics
Teresa Lavoie, PhD
Principal, Fish & Richardson
Jizu Yi, PhD
SVP, YZY Biopharma
David Ho, MD
Director, AIDS Center, Columbia Univ.
Jijie Gu, PhD
CSO/EVP, WuXi Biologics
Starts at 12/05/2020 8 a.m. (US EDT) | 12/05/2020 9 p.m. (Beijing)
Hover to view abstract
12/05/2020 8 a.m. EDT
Mitchell Ho, PhD, Sr. Investigator, LMB, NCI
12/05/2020 8:05 a.m. EDT
Next Wave of Innovation of Drug Discovery Driven by Antibody-based Multispecific and Functional Drugs
Jijie Gu, PhD, CSO/EVP, WuXi Biologics
12/05/2020 8:45 a.m. EDT
Development of KN046 - a PD-L1/CTLA-4 BsAb
Ting Xu, PhD, Founder/CEO, Alphamab Oncology
12/05/2020 9:15 a.m. EDT
CMC Challenges and Strategies for Bispecific Antibody Development
Jizu Yi, PhD, SVP, YZY Biopharma
12/05/2020 9:45 a.m. EDT
Bispecific γδ-T cell Engagers for Cancer Immunotherapy.
Paul Parren, PhD, Executive VP, Lava Therapeutics
12/05/2020 10:15 a.m. EDT
Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike.
David Ho, MD, Director, AIDS Center, Columbia Univ.
12/05/2020 10:45 a.m. EDT
Regulatory Challenges and opportunities for biological products
Audrey Jia, MD, PhD, Principal Consultant, DataRevive
12/05/2020 11:15 a.m. EDT
CAS Staff, , The Chinese Antibody Society
12/05/2020 12:45 p.m. EDT
Patent Protection Strategies for Bispecific Antibodies
Teresa Lavoie, PhD, Principal, Fish & Richardson
12/05/2020 1:15 p.m. EDT
Combining Computer Aided Design and Traditional Antibody Discovery and Engineering Technologies to Develop Multi-Specific Antibodies
Yue Liu, PhD, Founder/CEO, Ab Studio and Ab Therapeutics